<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636867</url>
  </required_header>
  <id_info>
    <org_study_id>5510/2018</org_study_id>
    <nct_id>NCT03636867</nct_id>
  </id_info>
  <brief_title>Laboratory, Cellular and Molecular Determinants of Clinical Success in Diabetic Patients With Critical Limb Ischemia</brief_title>
  <acronym>ECAD-CLI</acronym>
  <official_title>Prospective Evaluation of Laboratory, Cellular and Molecular Determinants of Clinical Success of the Treatment in Diabetic Patients With Critical Limb Ischemia (ECAD-CLI) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maria Cecilia Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maria Cecilia Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ECAD-CLI is an investigator-driven, prospective, single-center study. The aim of the
      study is to prospectively collect clinical, laboratory, angiographic, cellular and molecular
      variables related to prognosis and outcome in patients with diabetes mellitus and critical
      limb ischemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All consecutive patients admitted to Maria Cecilia Hospital will be enrolled in the ECAD-CLI
      study. According to interventional management of the patient the following data and samples
      will be prospectively collected and related to outcome:

        -  medical history, cardiovascular risk factors, clinical presentation

        -  information related to angiography of peripheral arteries. An independent core-lab will
           review angiographies to assess extent and severity of peripheral artery disease

        -  information related to medical treatment, including antithrombotic agents, antimicrobics
           and any treatment to permit wound healing

        -  blood sample to obtain DNA, RNA and serum

        -  patient undergoing surgery and/or debridement for wound/ulcer due to diabetic foot
           disease will receive biopsy for specimen collection

        -  atherosclerotic plaque sample in patients undergoing atherectomy for the treatment of
           the peripheral artery disease All clinical variables and information obtained from
           blood/tissue samples will be related to outcome.

      Any adverse events will be judged by an independent blinded committee.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Incidence of amputation</measure>
    <time_frame>1-year</time_frame>
    <description>Occurrence of major or minor amputation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound healing</measure>
    <time_frame>1-year</time_frame>
    <description>occurrence of wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WIfI class</measure>
    <time_frame>1-year</time_frame>
    <description>The Wound, Ischemia and Foot Infection is the most used classification for patients with diabetic foot disease. The classification ranges from 0 to 9. The scale includes 3 items: wound extension, presence and severity of ischemia, presence and severity of ischemia. Each item ranges from 0 to 3 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rutherford class</measure>
    <time_frame>1-year</time_frame>
    <description>The Rutherford classification is the most used scale to stratify patients with peripheral artery disease. The classification ranges from class I to class VI. Patients with critical limb ischemia show a class from IV to VI. The Rutherford class will be assessed in all patients at baseline and 1-year after to estimate the presence or not of improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of revascularization of peripheral arteries</measure>
    <time_frame>1-year</time_frame>
    <description>any procedure (percutaneous or surgical) of revascularization of peripheral arteries</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of major cardio and cerebrovascular adverse events (MACCE)</measure>
    <time_frame>1-year</time_frame>
    <description>cumulative occurrence of all-cause death, myocardial infarction, cerebrovascular accident</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Critical Limb Ischemia</condition>
  <condition>Critical Lower Limb Ischemia</condition>
  <condition>Diabetic Foot</condition>
  <arm_group>
    <arm_group_label>data and specimen collection</arm_group_label>
    <description>consecutive diabetic patients admitted to Maria Cecilia Hospital for critical limb ischemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data and specimen collection</intervention_name>
    <description>to identify laboratory, cellular and molecular determinants of clinical success after treatment, several clinical information and specimens will be collected by Authors from each patient</description>
    <arm_group_label>data and specimen collection</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      for each patient, according clinical presentation and type of intervention, the Authors will
      collect: i) blood sample for DNA extraction, RNA extraction and serum collection; plaque from
      patients undergoing endoarterectomy, tissue removed from foot ulcers requiring debridement or
      surgical manipulation
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with diabetes mellitus and critical limb ischemia admitted to hospital for
        medical/interventional management of the disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of diabetes mellitus in treatment with oral agents and/or insulin

          -  diagnosis of critical limb ischemia requiring medical and/or interventional treatment

        Exclusion Criteria:

          -  dialysis

          -  diagnosis or suspicion of malignancy

          -  life expectancy &lt;1 year

          -  inability to guarantee clinical follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Dalla Paola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maria Cecilia Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianluca Campo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit√† degli Studi di Ferrara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberta Zoli</last_name>
    <phone>0545217564</phone>
    <phone_ext>+39</phone_ext>
    <email>direzionescientifica-mch@gvmnet.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena Tenti</last_name>
    <phone>3391572707</phone>
    <phone_ext>+39</phone_ext>
    <email>etenti@gvmnet.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maria Cecilia Hospital</name>
      <address>
        <city>Cotignola</city>
        <state>Ravenna</state>
        <zip>48010</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Dalla Paola, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Sbarzaglia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Dalla Paola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

